The fen-phen controversy: Is regression another piece of the puzzle?

Mayo Clinic Proceedings

Volumn 74, Issue 12, 1999, Pages 1302-1304

  Asinger, R W ^a  

^a HENNEPIN COUNTY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANOREXIGENIC AGENT; FENFLURAMINE; PHENTERMINE;

ECHOCARDIOGRAPHY; EDITORIAL; HEART HEMODYNAMICS; HUMAN; OBESITY; VALVULAR HEART DISEASE;

EID: 0032758778     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/74.12.1302     Document Type: Editorial

References (25)

1. HM Connolly JL Crary MD McGoon Valvular heart disease associated with fenfluramine-phentermine [published correction appears in N Engl J Med. 1997,337:1783] N Engl J Med 337 1997 581 588
2. DD Hensrud HM Connolly M Grogan FA Miller KR Bailey MD Jensen Echocardiographic improvement over time after cessation of use of fenfluramine and phentermine Mayo Clin Proc 74 1999 1191 1197
3. Cardiac valvulopathy associated with exposure to fenfluramine or dexfcnfluramine: US Department of Health and Human Services interim public health recommendations, November 1997 MMWR Morb Mortal Wkly Rep 46 1997 1061 1066
4. Food and Drug Administration Health advisory on fenflur-amine/phentermine for obesity [press release, No. P97-20, July 8, 1997] Available at: http://www.fda.gov/bbs/topics/NEWS/NEW00575.html Accessed October 26, 1999.
5. DJ Graham L Green Further cases of valvular heart disease associated with fenfluramine-phentermine [letter] N Engl J Med 337 1997 635
6. S Rasmussen BC Corya RD Classman Valvular heart discase associated with fenfluramine-phentermine [Letter] N Engl J Med 337 1997 I773
7. TA Wadden Rl Berkowitz F Silvestry The fen-phen finale: a study of weight loss and valvular heart disease Obes Res 6 1998 278 284
8. RL Bowen JP Foreyt WSC Poston II Echocardiographic assessment of patients receiving long-term treatment with ano-rexiant medications Endocr Pract 5 1999 17 23
9. X Kurz A Van Ermcn Valvular heart disease associated with fenfluramine-phentermine [letter] N Engl J Med 337 1997 1772 1773
10. AJ Burger HB Sherman MJ Charlamb Low prevalence of valvular heart disease in 226 phentermine-fenfluramine protocol subjects prospectivcly followed for up to 30 months J Am Coll Cardlol 34 1999 1153 1158
11. MA Khan CA Herzog JV St Peter The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs N Engl J Med 339 1998 713 718
12. NJ Weissman JF Tighe Jr JS Gottdiener JT Gwynne Sustained-Release Dexfenfluramine Study Group An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine. sustained-release dexfenfluramine, or placebo N Engl J Med 339 1998 725 732
13. H Jick C Vasilakis LA Weinrauch CR Meier SS Jick IE Derby A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation N Engl J Med 339 1998 719 724
14. DH Ryan GA Bray F Helmcke Serial echocardiographic and clinical evaluation of valvular regurgitation before, during, and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine Obes Res 7 1999 313 322
15. R Li MK Serdula DF Williamson BA Bowman DJ Graham L Green Dose-effect of fenfluramine use on the severity of valvular heart disease among fen-phen patients with valvulopathy Int J Obes Relat Metab Disord 23 1999 926 928
16. MM Redfield WJ Nicholson WD Edwards AJ Tajik Valve disease associated with ergot alkaloid use: echocardiographic and pathologic correlations Ann Intern Med 117 1992 50 52
17. PA Pellikka AJ Tajik BK Khandheria Carcinoid heart disease: clinical and echocardiographic spectrum in 74 patients Circulation 87 1993 1188 1196
18. PJ Wellman TJ Maher Synergistic interactions between fenfluramine and phentermine Inl J Obes Relat Metab Disord 23 1999 723 732
19. RJ Wurtman TJ Maher I Ulus Valvulopathy or primary pulmonary hypertension as possible consequences of administering a serotonin uptake blocker with a monoamine oxidasc inhibitor (“phen-fen”) [editorial) Cardiovasc Rev Rep 20 1999 312 314
20. RO Bonow E Lakatos BJ Maron SE Epstein Serial long-term assessment of the natural history of asymptomatic patients with chronic aortic regurgitation and normal left ventricular systolic function Circulation 84 1991 1625 1635
21. LB Cannistra AJ Cannistra Regression of multivalvular regurgitation after the cessation of fenfluramine and phentermine treatment [letter] N Engl J Med 339 1998 771
22. DH Ryan GA Bray F Greenway F Helmckc Does valvulopathy in patients treated with appetite suppressants regress over time? [abstract] Gilt J Obes Relat Metab Disord 23 suppl 5 1999 S63
23. MC Mancini CC Leite M Grinberg A Halpern Regression of heart-valve abnormalities after discontinuation of dexfenfluramine treatment [abstract] Int J Obes Relat Metab Disord 23 suppl 5 1999 S178
24. NB Schiller Fen/phen and valvular heart disease: if it sounds too bad to be true, perhaps it isn't [editorial] J Am Coll Cardiol 34 1999 1159 1162
25. AL Klein DJ Burstow AJ Tajik Age-related prevalence of valvular regurgitation in normal subjects: a comprehensive color flow examination of 118 volunteers J Am Soc Echocardiogr 3 1990 54 63